Shot of vedolizumab skin injection for active bowel inflammation
Part of Digestive system clinical trials.
This study tests whether a weekly/regular skin injection version of vedolizumab can help adults with moderate to severe ulcerative colitis or Crohn’s disease who did not fully respond to other treatments or TNF blockers. It may help by moving you from an intravenous (IV) infusion to a self/clinic injection option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate-to-severe ulcerative colitis or Crohn’s disease currently
- You tried standard treatments or a TNF blocker but had not enough benefit, lost benefit, or could not tolerate them
- You already showed benefit after at least 2 vedolizumab IV infusions
- You do not have a known allergic reaction to vedolizumab (such as trouble breathing, hives, flushing, or fast heartbeat)
- You do not have a serious active infection (like tuberculosis, CMV, sepsis, listeria, or other weak-immunity infections such as PML)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This study compares two ways of taking the IBD medicine vedolizumab (injecting under the skin versus through an IV line). You'll use a smartphone app to report your symptoms, so you can participate from home and help doctors learn which option works better.
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
This program lets children and teenagers with ulcerative colitis or Crohn's disease continue receiving vedolizumab (a biologic medicine) through an IV if it's already helping them. It's for those who have no better treatment options and want to keep getting the same medicine.
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.